Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

End-of-day quote. End-of-day quote  - 03/04
55.605 USD   +0.31%
04/28DJValeant Discloses Pay for New CEO
04/28DJValeant Discloses Pay for New CEO
04/26DJCEO's Departure Rattles Perrigo Shareholders -- WSJ
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 08:20pm CEST

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

SOURCE Mylan Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MYLAN INC
04/28DJValeant Discloses Pay for New CEO
04/28DJValeant Discloses Pay for New CEO
04/26DJCEO's Departure Rattles Perrigo Shareholders -- WSJ
04/26DJCEO Exits Show Room at Top Can Be Lonely -- WSJ
04/25DJAs Its CEO Leaves for Valeant, Perrigo Continues to Struggle -- 5th Update
04/25DJAs Its CEO Leaves for Valeant, Perrigo Continues to Struggle -- 4th Update
04/25DJAs Its CEO Leaves to for Valeant, Perrigo Continues to Struggle -- 2nd Update
04/25DJValeant Names Joseph Papa as New CEO--Update
04/25DJPerrigo Shares Tumble as CEO Leaves for Valeant, Guidance Cut Again -- Update
04/25DJValeant Names Joseph Papa as New CEO--Update